Standout Papers

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell... 2014 2026 2018 2022 1.8k
  1. Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study (2016)
    David F. McDermott, Jeffrey A. Sosman et al. Journal of Clinical Oncology
  2. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer (2014)
    Thomas Powles, Joseph P. Eder et al. Nature

Immediate Impact

18 by Nobel laureates 13 from Science/Nature 82 standout
Sub-graph 1 of 20

Citing Papers

Current best practice for bladder cancer: a narrative review of diagnostics and treatments
2022 Standout
Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells
2021 StandoutNobel
3 intermediate papers

Works of Gregg Fine being referenced

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature

Author Peers

Author Last Decade Papers Cites
Gregg Fine 2744 802 426 1501 885 32 3.7k
Cristina Cruz 2695 626 231 1216 648 36 3.6k
Kumudu Pathiraja 2593 564 290 994 1119 36 3.3k
Ira Wollner 2580 301 243 1341 727 31 3.3k
Denise Frosina 2240 381 421 1849 1007 49 4.1k
Tracee L. McMiller 4171 358 284 2553 1050 26 5.0k
Monica V. Goldberg 3080 454 904 2150 629 18 4.4k
Zachary Boyd 2300 696 247 1167 639 24 3.6k
Ani Sarkis Balmanoukian 2805 527 138 1099 1077 73 3.4k
Jennifer H. Yearley 3642 636 301 2595 1349 56 5.5k
Jérémy Goc 2386 420 214 2457 722 27 3.8k

All Works

Loading papers...

Rankless by CCL
2026